These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 23276981)

  • 41. Novel vectors for in vivo gene delivery to vascular tissue.
    White K; Nicklin SA; Baker AH
    Expert Opin Biol Ther; 2007 Jun; 7(6):809-21. PubMed ID: 17555367
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Viral-mediated gene therapy in pediatric neurological disorders.
    Peng J; Zou WW; Wang XL; Zhang ZG; Huo R; Yang L
    World J Pediatr; 2024 Jun; 20(6):533-555. PubMed ID: 36607547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adeno-Associated Virus Vector for Central Nervous System Gene Therapy.
    Zhu D; Schieferecke AJ; Lopez PA; Schaffer DV
    Trends Mol Med; 2021 Jun; 27(6):524-537. PubMed ID: 33895085
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin.
    Scott JM; Li S; Harper SQ; Welikson R; Bourque D; DelloRusso C; Hauschka SD; Chamberlain JS
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S23-9. PubMed ID: 12206791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Barriers to non-viral vector-mediated gene delivery in the nervous system.
    Pérez-Martínez FC; Guerra J; Posadas I; Ceña V
    Pharm Res; 2011 Aug; 28(8):1843-58. PubMed ID: 21225319
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Viral Vectors for Gene Therapy: Translational and Clinical Outlook.
    Kotterman MA; Chalberg TW; Schaffer DV
    Annu Rev Biomed Eng; 2015; 17():63-89. PubMed ID: 26643018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection.
    Huang L; Wan J; Wu Y; Tian Y; Yao Y; Yao S; Ji X; Wang S; Su Z; Xu H
    Life Sci; 2021 Apr; 270():119142. PubMed ID: 33524419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Applications of lentiviral vectors for biology and gene therapy of neurological disorders.
    Lundberg C; Björklund T; Carlsson T; Jakobsson J; Hantraye P; Déglon N; Kirik D
    Curr Gene Ther; 2008 Dec; 8(6):461-73. PubMed ID: 19075629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna.
    Taghian T; Marosfoi MG; Puri AS; Cataltepe OI; King RM; Diffie EB; Maguire AS; Martin DR; Fernau D; Batista AR; Kuchel T; Christou C; Perumal R; Chandra S; Gamlin PD; Bertrand SG; Flotte TR; McKenna-Yasek D; Tai PWL; Aronin N; Gounis MJ; Sena-Esteves M; Gray-Edwards HL
    Mol Ther; 2020 Feb; 28(2):411-421. PubMed ID: 31813800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system.
    Burger C; Gorbatyuk OS; Velardo MJ; Peden CS; Williams P; Zolotukhin S; Reier PJ; Mandel RJ; Muzyczka N
    Mol Ther; 2004 Aug; 10(2):302-17. PubMed ID: 15294177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The status of gene vectors for the treatment of diabetes.
    Zaia JA
    Cell Biochem Biophys; 2007; 48(2-3):183-90. PubMed ID: 17709888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vectors for gene therapy of cardiovascular disease.
    Dedieu JF; Mahfoudi A; Le Roux A; Branellec D
    Curr Cardiol Rep; 2000 Jan; 2(1):39-47. PubMed ID: 10980871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors.
    Miyake N; Miyake K; Yamamoto M; Hirai Y; Shimada T
    Brain Res; 2011 May; 1389():19-26. PubMed ID: 21397590
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Challenge of Gene Therapy for Neurological Diseases: Strategies and Tools to Achieve Efficient Delivery to the Central Nervous System.
    Piguet F; de Saint Denis T; Audouard E; Beccaria K; André A; Wurtz G; Schatz R; Alves S; Sevin C; Zerah M; Cartier N
    Hum Gene Ther; 2021 Apr; 32(7-8):349-374. PubMed ID: 33167739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke.
    Lawrence MS; McLaughlin JR; Sun GH; Ho DY; McIntosh L; Kunis DM; Sapolsky RM; Steinberg GK
    J Cereb Blood Flow Metab; 1997 Jul; 17(7):740-4. PubMed ID: 9270490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment.
    Chen W; Yao S; Wan J; Tian Y; Huang L; Wang S; Akter F; Wu Y; Yao Y; Zhang X
    J Control Release; 2021 May; 333():129-138. PubMed ID: 33775685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gene delivery using herpes simplex virus vectors.
    Burton EA; Fink DJ; Glorioso JC
    DNA Cell Biol; 2002 Dec; 21(12):915-36. PubMed ID: 12573050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Strategies for retargeted gene delivery using vectors derived from lentiviruses.
    Bartosch B; Cosset FL
    Curr Gene Ther; 2004 Dec; 4(4):427-43. PubMed ID: 15578992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overcoming barriers in non-viral gene delivery for neurological applications.
    Tasset A; Bellamkonda A; Wang W; Pyatnitskiy I; Ward D; Peppas N; Wang H
    Nanoscale; 2022 Mar; 14(10):3698-3719. PubMed ID: 35195645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current status of non-viral gene therapy for CNS disorders.
    Jayant RD; Sosa D; Kaushik A; Atluri V; Vashist A; Tomitaka A; Nair M
    Expert Opin Drug Deliv; 2016 Oct; 13(10):1433-45. PubMed ID: 27249310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.